Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier de Bethune

About this trial

During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.

Eligibility criteria

Qualifiers

Patient ≥ 18 years old

Patient hospitalized in an intensive care unit

Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspected non-obstructive

Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 seconds and/or cardiovascular SOFA ≥ 1 and/or lactatemia > 2mmol/L)

Disqualifiers

Pregnant or breastfeeding woman

Known chronic renal insufficiency of any stage

Cardio-renal and hepato renal syndrome

Unstable hemodynamic state: refractory shock

Trial design

Treatments tested in this trial

  • ACETATE based dialysate
  • CITRATE based dialysate

Treatment groups

48 Participants
are divided into 2 treatment groups

Sponsors and collaborators